Navigation Links
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Date:5/30/2009

Clinical Data Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 30 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today presented data from a Phase I clinical trial of its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Florida.

Dr. E. Gabriela Chiorean, from the Indiana University Simon Cancer Center in Indianapolis, IN presented the interim Phase I data on SF1126 in 36 advanced solid tumor patients. The majority of patients were heavily pretreated with a median of four prior chemotherapy regimens. Sixteen of 36 (44%) patients achieved disease stabilization with a median duration of 12 weeks. Of note, a GIST, endometrial, and prostate cancer patient each achieved durable stable disease for 20 weeks (5 mos.). These specific tumor types are associated with aberrations of the PI3K pathway that commonly lead to resistance and poor prognostic outcomes.

Pharmacodynamic analysis of tumor tissue confirmed inhibition of the PI3K pathway by complete absence of a downstream target (pS6). In contrast, a normal tissue (skin) demonstrated no inhibition providing evidence of tumor selectivity of SF1126. Pharmacokinetics displayed dose proportionality and no accumulation between cycles.

SF1126 was well tolerated. The most common side effects were grade 1 or 2 vomiting (42%), nausea (39%), diarrhea (33%), fever (22%), fatigue (19%), chills (14%), and puritis (11%). There were two patients with grade 3 toxicity, one with diarrhea, the other with urticaria and pruritis. Notably, there were no clinically significant changes in glucose or insulin levels reported.

"Based on these Phase I results we are encouraged that SF1126 is well tolerated and may hold promise for the treatment of solid tumor maligna
'/>"/>

SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
3. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
4. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
7. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
8. Cardiologists Tackle Next Frontier in Cardiovascular Disease
9. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   Decision Resources Group finds that ... frequent dosing as the highest unmet need in ... on both patients and providers associated with monthly ... which are the current standard of care. The ... in development for dosing every two to three ...
(Date:7/2/2015)... , July 2, 2015  Konica Minolta, Inc. (Konica ... that it has acquired Sawae Technologica Ltda., an X-ray ... Brazil , through its Brazilian healthcare sales company, ... Local Brazil market ... increasing population exceeding 200 million, significant healthcare technical advancements ...
(Date:7/2/2015)... Ill. , July 2, 2015  AbbVie (NYSE: ... results on Friday, July 24, 2015, before the market ... of the earnings conference call at 8 a.m. Central ... AbbVie,s Investor Relations website at www.abbvieinvestor.com . An ... 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... treated with Satraplatin Demonstrated Statistically,Significant Improvement in ... March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion,Corporation and ... from,the double-blind, randomized satraplatin Phase 3 registrational,trial, ... Cancer) which were presented today at the ...
... Scientists,at WEHI have made a discovery with potentially ... undergoing,cancer chemotherapy. , The research team led by ... platelet life span is controlled by two key,molecules. ... new,drug to prolong the life span of platelets ...
Cached Medicine Technology:Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 2Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 3Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 4Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 5Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 6Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress 7Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 2Major Discovery Raises Prospect of Better Patient Care By Improving,Platelet Life Span 3
(Date:7/3/2015)... (PRWEB) , ... July 03, ... ... announced the sessions and speaker lineup for its 2015 Annual Conference ... place August 6-8, 2015 at the Renaissance Orlando at SeaWorld in Orlando, ...
(Date:7/3/2015)... ... 03, 2015 , ... The Erie County Bar Association Institute ... The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law Offices. ... investigating these types of cases. , Each year, New York State residents are ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a Stick ” was featured ... coolest technology products available to consumers. Amanda Forstrom, a technology expert and special reporter ... great for documenting memories. , Almost every smartphone has an incredibly powerful camera built ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce ... sweetFrog store located in the Lone Star State. The premium frozen yogurt chain was listed ... store, which opened June 19 in the Village at Bachman Lake, is located at:, 3701 ...
(Date:7/2/2015)... ... , ... Many Fourth of July celebrations will include fireworks this summer, so ... sharing some tips to promote the proper use of fireworks. , According to the ... daily with fireworks-related injuries in the month surrounding the Fourth of July. Amica is ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... study suggests, , WEDNESDAY, Jan. 20 (HealthDay News) -- ... drills, say German researchers. , They found that firing ... tooth structure beneath the enamel coating -- reduced the ... results suggest that plasma jets could be used to ...
... ... , ... MD (Vocus) January 20, 2010 -- Healthy Directions, LLC, is proud to announce ... top quality natural solutions to today’s most pressing health concerns. The new Web ...
... CHICAGO , Jan. 20 According to ... American Journal of Health Promotion , a peer-reviewed journal devoted ... activities within an incentive-based health insurance wellness program had significantly ... data over one year of 948,974 adult members of ...
... benefit patients, survey reports , WEDNESDAY, Jan. 20 (HealthDay ... medical students think that knowledge of complementary and alternative ... , Complementary and alternative medicine, or CAM, includes ... , "Even with the high prevalence of CAM use ...
... ... decisions are substantiated by accurate data analysis and reporting, four colleges within the ... , ... NH (PRWEB) January 20, 2010 -- In today’s technology-driven environment, where sound business ...
... ... On January 2 of this year, Freedom From Covert Harassment and Surveillance ... This event coincides with January as National Stalking Awareness Month. Organized ... may not even know why the stalking is occurring, has emerged with ...
Cached Medicine News:Health News:Healthy Directions, LLC, Announces Launch of Online Resource for Premium Quality Natural Health Solutions 2Health News:Research Indicates Participants in Incentive-Based Health Promotion Programs Have Lower Healthcare Costs 2Health News:Research Indicates Participants in Incentive-Based Health Promotion Programs Have Lower Healthcare Costs 3Health News:Research Indicates Participants in Incentive-Based Health Promotion Programs Have Lower Healthcare Costs 4Health News:New Hampshire Community Colleges Choose Rapid Insight for Data Reporting Needs 2Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 2Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 3Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 4
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Designated most popular model or size....
Designated most popular model or size. Double-ended. 2 mm wide....
Desmarres Retractor Size 4...
Medicine Products: